0000899243-23-004233.txt : 20230207 0000899243-23-004233.hdr.sgml : 20230207 20230207183501 ACCESSION NUMBER: 0000899243-23-004233 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230202 FILED AS OF DATE: 20230207 DATE AS OF CHANGE: 20230207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Violin Jonathan CENTRAL INDEX KEY: 0001730615 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36483 FILM NUMBER: 23596530 MAIL ADDRESS: STREET 1: 955 CHESTERBROOK BOULEVARD STREET 2: SUITE 200 CITY: CHESTERBROOK STATE: PA ZIP: 19087 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Viridian Therapeutics, Inc.\DE CENTRAL INDEX KEY: 0001590750 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 471187261 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 203 CRESCENT STREET STREET 2: BLDG. 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 617.272.4600 MAIL ADDRESS: STREET 1: 203 CRESCENT STREET STREET 2: BLDG. 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: MIRAGEN THERAPEUTICS, INC. DATE OF NAME CHANGE: 20170213 FORMER COMPANY: FORMER CONFORMED NAME: MIRAGEN THERAPEUTICS, INC. DATE OF NAME CHANGE: 20170213 FORMER COMPANY: FORMER CONFORMED NAME: SIGNAL GENETICS, INC. DATE OF NAME CHANGE: 20140710 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2023-02-02 2023-02-07 1 0001590750 Viridian Therapeutics, Inc.\DE VRDN 0001730615 Violin Jonathan C/O VIRIDIAN THERAPEUTICS, INC. 221 CRESCENT STREET, SUITE 401 WALTHAM MA 02453 1 1 0 0 Chief Executive Officer Common Stock 2023-02-02 4 M 0 50000 0.15 A 530905 D Common Stock 2023-02-02 4 S 0 50000 36.80 D 480905 D Stock Option (Right to Buy) 0.15 2023-02-02 4 M 0 50000 0.00 D 2030-09-23 Common Stock 50000 239205 D Due to a broker error, the Form 4 filed by the Reporting Person on February 3, 2023 incorrectly reported the source of shares sold on February 2, 2023 pursuant to the Reporting Person's Rule 10b5-1 trading plan. This amendment reflects the exercise of stock options for 50,000 shares of common stock, which were the source of the shares sold. This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $36.1523 to $37.3689. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. The option vested 25% on September 23, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. /s/ Lara Meisner, Attorney-in-Fact for Jonathan Violin 2023-02-07